ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 219,28
-1,05%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. TG Therapeutics Inc (TGTX)

  7. TG Therapeutics Inc (TGTX) Actualités

TGTX TG Therapeutics Inc

16,01
-0,41 (-2,50%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
TG Therapeutics Inc TGTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,41 -2,50% 16,01 01:59:49
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
16,75 15,96 17,00 16,19 16,42
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202413:00GLOBETG Therapeutics Provides Business Update and Reports First..
30/4/202422:55GLOBETG Therapeutics to Host Conference Call on First Quarter..
18/4/202413:30GLOBETG Therapeutics Announces Additional Data Presentations for..
18/4/202413:00GLOBETG Therapeutics Awarded National Contract by the Department..
15/4/202413:30GLOBETG Therapeutics Announces Presentation of Data for BRIUMVI®..
08/3/202413:30GLOBETG Therapeutics Announces Schedule of Data Presentations for..
01/3/202413:30GLOBETG Therapeutics Announces Presentation of Data for BRIUMVI®..
29/2/202423:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
28/2/202413:24EDGAR2Form 8-K - Current report
28/2/202413:00GLOBETG Therapeutics Provides Business Update and Reports Fourth..
27/2/202413:30GLOBETG Therapeutics Announces Issuance of Additional Patents for..
26/2/202413:00GLOBETG Therapeutics Announces European Launch of BRIUMVI®..
23/2/202413:30GLOBETG Therapeutics to Host Conference Call on Fourth Quarter..
20/2/202413:30GLOBETG Therapeutics Announces Schedule of Data Presentations for..
15/2/202403:53EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
14/2/202421:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/1/202422:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/1/202413:37EDGAR2Form 8-K - Current report
10/1/202413:00GLOBETG Therapeutics Provides Preliminary Fourth Quarter and Full..
09/1/202415:20APSBiotech Massively Bid Up Before Opening Bell
09/1/202413:00GLOBETG Therapeutics Announces Global License Agreement with..
09/1/202400:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202417:02EDGAR2Form 144 - Report of proposed sale of securities
05/1/202413:30GLOBETG Therapeutics to Participate in the 42nd Annual J.P...
03/1/202422:46EDGAR2Form 144 - Report of proposed sale of securities
27/11/202313:30GLOBETG Therapeutics to Participate in the 6th Annual Evercore..
06/11/202323:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202312:30GLOBETG Therapeutics to Participate in the 5th Annual Guggenheim..
01/11/202312:33EDGAR2Form 8-K - Current report
01/11/202312:30GLOBETG Therapeutics Provides Business Update and Reports Third..
30/10/202312:30GLOBETG Therapeutics to Host Conference Call on Third Quarter..
12/10/202317:00GLOBETG Therapeutics Announces Presentation of Data for BRIUMVI..
11/10/202316:30GLOBETG Therapeutics Announces Presentation of Data for BRIUMVI..
02/10/202313:30GLOBETG Therapeutics Announces Schedule of Data Presentations for..
29/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/9/202313:30GLOBETG Therapeutics to Participate in the 2023 Cantor Global..
07/9/202313:30GLOBETG Therapeutics to Participate in the H.C. Wainwright 25th..
14/8/202315:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/8/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202313:29EDGAR2Form 8-K - Current report
01/8/202313:15GLOBETG Therapeutics Provides Business Update and Reports Second..
01/8/202313:00GLOBETG Therapeutics and Neuraxpharm Announce Ex-US..
31/7/202314:30GLOBETG Therapeutics to Host Conference Call on Second Quarter..
05/6/202313:30GLOBETG Therapeutics to Participate in the 2023 Jefferies..
02/6/202315:15GLOBETG Therapeutics Announces Presentation of Data from the..
01/6/202315:15GLOBETG Therapeutics Announces European Commission Approval for..
31/5/202313:30GLOBETG Therapeutics Announces Data from the ULTIMATE I & II..

Dernières Valeurs Consultées

NASDAQ
TGTX
TG Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés